Almac Discovery, a research driven drug discovery company and member of the Almac Group, has announced the nomination of a new pre-clinical candidate molecule (ALM-401), a First in Class Bispecific Antibody Drug Conjugate (ADC) for the treatment of refractory lung...
https://www.youtube.com/watch?v=YpcwHA7GG0w Hear from Elasmogen's CEO, Prof. Caroline Barelle, how The Scottish National Investment Bank helps to develop next-generation therapeutic drugs, with the potential to improve the health of people in Scotland and globally.
On 13th of November, as part of the Excelerate program, advanced higher biology students from Harlaw Academy visited Elasmogen. The students participated in interactive theory and practical sessions learning from Elasmogen’s scientists about fundamental ELISA and PCR...
Insider.co.uk has announced today the shortlist for the Deal & Dealmakers Awards. Elasmogen is nominated for Early Stage Deal of the Year in partnership with RBC Brewin Dolphin. Please see here the link to the story.
On 10th of May Elasmogen team took part in the regional event hosted by the BIA in collaboration with opportunity North East. The event took place at the new BioHub. Our principal scientist and program lead Dr Obinna Ubah was in the panel along with other life science...
Elasmogen Ltd has announced the appointment of Jane Dancer as the Chair of the Board. Jane joined Elasmogen as a non-executive director in April 2022 on the back of new investment from BGF, The Bank and Scottish Enterprise who joined existing investors, Deepbridge...
Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced a global license agreement that gives Elasmogen exclusive access to Soteria® and Phloral® technologies for oral colonic delivery of therapeutic...
Aberdeen, Scotland, 18 May 2022: Elasmogen – a biopharmaceutical company discovering and developing new therapeutics using its unique soloMERTM platform – has secured £8 million investment. The funding round was led by BGF and Scottish National Investment Bank (The...
MADISON – Small, unique antibody-like proteins known as VNARs derived from the immune systems of sharks can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study published Dec. 16. The new...
Expertise in drug discovery and the treatment of life-changing inflammatory diseases has been rewarded with prestigious funding via the UKRI’s Future Leaders Fellowship (FLF) Scheme. Dr Obinna Ubah, heads up Scottish biotechnology company Elasmogen Ltd’s auto-immune...
At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections January 25th 2021: Aberdeen, Scotland: Elasmogen Ltd, the pioneering biopharmaceutical company leading the development of VNAR...
New grants across multiple territories cover the use of humanised or de-immunised VNARs for therapeutic applications December 9th 2020: Aberdeen, Scotland: Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, today announces a...